[go: up one dir, main page]

ES2165269A1 - Derivados de alfa-cetoamidas. - Google Patents

Derivados de alfa-cetoamidas.

Info

Publication number
ES2165269A1
ES2165269A1 ES009900918A ES9900918A ES2165269A1 ES 2165269 A1 ES2165269 A1 ES 2165269A1 ES 009900918 A ES009900918 A ES 009900918A ES 9900918 A ES9900918 A ES 9900918A ES 2165269 A1 ES2165269 A1 ES 2165269A1
Authority
ES
Spain
Prior art keywords
alpha
ketoamides
sup
derivatives
ketoamide derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES009900918A
Other languages
English (en)
Inventor
David Nigel Hurst
Philip Stephen Jones
Paul Brittain Kay
Tony Michael Raynham
Francis Xavier Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of ES2165269A1 publication Critical patent/ES2165269A1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Derivados de alfa-cetoamidas. La invención se refiere a {al}- cetoamidas de fórmula general (I) en donde R{sup,1} a R{sup,12} tienen el significado dado en la descripción, y sus sales, las cuales son inhibidoras de proteinasas víricas útiles como agentes antivíricos, en especial para el tratamiento o la profilaxis de infecciones causadas por los virus de la hepatitis C, hepatitis G y GB humanos.
ES009900918A 1998-05-06 1999-05-05 Derivados de alfa-cetoamidas. Pending ES2165269A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9809664.7A GB9809664D0 (en) 1998-05-06 1998-05-06 a-Ketoamide derivatives

Publications (1)

Publication Number Publication Date
ES2165269A1 true ES2165269A1 (es) 2002-03-01

Family

ID=10831533

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009900918A Pending ES2165269A1 (es) 1998-05-06 1999-05-05 Derivados de alfa-cetoamidas.

Country Status (8)

Country Link
US (1) US6187905B1 (es)
JP (1) JPH11349597A (es)
CA (1) CA2270847A1 (es)
DE (1) DE19920966A1 (es)
ES (1) ES2165269A1 (es)
FR (1) FR2778406B1 (es)
GB (2) GB9809664D0 (es)
IT (1) IT1312558B1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102206247B (zh) 2000-07-21 2013-03-27 默沙东公司 一种具有HCV NS3/NS4a蛋白酶抑制活性的化合物
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
JP2004504407A (ja) * 2000-07-21 2004-02-12 コルバス・インターナショナル・インコーポレイテッド Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
JP4452441B2 (ja) 2000-07-21 2010-04-21 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US20030176689A1 (en) * 2001-12-14 2003-09-18 Michael Joyce Inhibitors of hepatitis C virus protease
US7119072B2 (en) * 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
WO2004076478A1 (ja) * 2003-02-28 2004-09-10 Yoshiaki Kiso βセクレターゼ阻害活性を有するペプチド誘導体
ES2297424T3 (es) * 2003-05-21 2008-05-01 Boehringer Ingelheim International Gmbh Compuestos inhibidores de la hepatitis c.
DE602004031645D1 (de) * 2003-09-22 2011-04-14 Boehringer Ingelheim Pharma Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
EP1730167B1 (en) * 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
UY29016A1 (es) * 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
JP4914355B2 (ja) * 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
US20070027067A1 (en) * 2005-05-13 2007-02-01 Felicia Etzkorn Transition-state Inhibitors of Pin1, alpha-Ketoamide-containing peptidomimetics, and synthesis thereof
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
JP2012512172A (ja) * 2008-12-15 2012-05-31 タイゲン バイオテクノロジー カンパニー，リミテッド ピペリジン誘導体の立体選択的合成
CN102093260B (zh) * 2009-12-14 2014-03-05 太景生物科技股份有限公司 哌啶衍生物的立体有择合成
CN102971286B (zh) * 2010-06-16 2015-08-26 美迪维尔英国有限公司 用于治疗例如自身免疫病症、过敏和慢性疼痛病状的新组织蛋白酶s蛋白酶抑制剂
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
FR2981071B1 (fr) * 2011-10-10 2014-02-07 Centre Nat Rech Scient Synthese versatile et stereospecifique d'acides amines gamma,delta-insatures par la reaction de wittig
CN105837657B (zh) * 2016-04-21 2019-08-23 陈铭 无氨基酸的多肽化学全合成法
DK3464336T3 (da) 2016-06-01 2022-05-09 Athira Pharma Inc Forbindelser
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
WO2022265577A2 (en) * 2021-06-15 2022-12-22 Agency For Science, Technology And Research Coronavirus enzyme modulators, methods of synthesis and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035308A1 (en) * 1994-06-17 1995-12-28 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
WO1998017679A1 (en) * 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO1998022496A2 (en) * 1996-11-18 1998-05-28 F. Hoffmann-La Roche Ag Antiviral peptide derivatives
WO1999007734A2 (en) * 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU726207B2 (en) * 1996-10-18 2000-11-02 Syntex (U.S.A.) Inc. IL-12 gene expression and delivery systems and uses
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035308A1 (en) * 1994-06-17 1995-12-28 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
WO1998017679A1 (en) * 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO1998022496A2 (en) * 1996-11-18 1998-05-28 F. Hoffmann-La Roche Ag Antiviral peptide derivatives
WO1999007734A2 (en) * 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues

Also Published As

Publication number Publication date
GB2338482A (en) 1999-12-22
FR2778406A1 (fr) 1999-11-12
GB9809664D0 (en) 1998-07-01
DE19920966A1 (de) 2000-01-13
FR2778406B1 (fr) 2003-05-09
ITMI990950A1 (it) 2000-11-04
JPH11349597A (ja) 1999-12-21
IT1312558B1 (it) 2002-04-22
CA2270847A1 (en) 1999-11-06
US6187905B1 (en) 2001-02-13
GB9910384D0 (en) 1999-07-07

Similar Documents

Publication Publication Date Title
ES2165269A1 (es) Derivados de alfa-cetoamidas.
UY28084A1 (es) Derivados antivirales de nucleosidos
UY27333A1 (es) Nucleótidos 4` sustituidos
ECSP055801A (es) Compuestos benzofuránicos, composiciones y métodos para el tratamiento y profilaxis de infecciones virales de hepatitis c y enfermedades asociadas
ME00558A (en) Pyrazole derivatives for treating hiv
DK1706403T3 (da) Imidazo[4,5-c]pyridinforbindelser og fremgangsmåder til antiviral behandling
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
ES2139195T3 (es) Derivados de sulfonamidas como inhibidores de la aspartil-proteasa.
DK1353911T3 (da) Antivirale midler
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
MX9403380A (es) Inhibidores de proteasa de vih utiles para el tratamiento de sida.
CY1115580T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξικης πιπεραζινης
BRPI0514425A (pt) inibidores de rna polimerase dependente de rna do vìrus da hepatite c, e composições e tratamentos usando os mesmos
DOP2003000641A (es) Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
CY1113194T1 (el) Συνθεση και αντιϊικη δραστικοτητα παραγωγων υποκατεστημενης αζαϊνδολοοξοοξικης πιπεραζινης
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
MX9307821A (es) Nueva clase de inhibidores de proteasa aspartilo.
BR0012243A (pt) Triflúor butenos nematocidas
DK1569929T3 (da) Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner
BRPI0507675A (pt) derivados de 2'-c-metil nucleosìdeo
PA8466101A1 (es) Agentes terapeuticos
DK1140113T3 (da) Anvendelse af bisphosphonater til profylakse og behandling af infektiøse processer
MX9700414A (es) Agentes antivirales de difluoroestatona.
PA8590801A1 (es) Derivados de nucleosido antivirales

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020301

Kind code of ref document: A1

Effective date: 20020301

FC2A Grant refused

Effective date: 20040212